Giant Cell Arteritis

1. THE 2-MINUTE PHYSIOLOGY (Rapid Pathophysiology)

• Mechanical Vessel Damage: Giant Cell Arteritis (GCA) is an inflammatory vasculopathy that targets medium-sized and large arteries with well-developed wall layers and adventitial vasa vasorum. The inflammatory cascade leads to thickening, fragmentation of the arterial elastic lamina, and intimal hyperplasia, causing luminal stenosis and subsequent distal tissue ischemia.
• Anatomical Distribution: While GCA is classically known as temporal arteritis due to its predilection for the superficial temporal and occipital branches of the external carotid artery, it also involves major branches of the aorta, including the ophthalmic, vertebral, distal subclavian arteries, and the thoracic aorta.
• Optic Nerve Ischemia: The most feared complication of GCA is irreversible blindness. This occurs when severe inflammation of the posterior ciliary arteries impairs perfusion to the optic nerve head, leading to anterior ischemic optic neuropathy (AION) or retinal/optic nerve ischemia.

2. THE BEDSIDE ACTION PLAN (Rapid ER Management)

• Hyperacute Visual and Neurological Assessment:
• Meticulously check and document visual acuity (the vital sign of the eye) in all patients presenting with visual complaints.
• Check intraocular pressure (IOP) to rule out acute angle-closure glaucoma as a painful visual loss mimic.
• Perform a comprehensive neurological and vascular exam: screen for posterior circulation stroke syndromes (vertebral artery involvement), assess peripheral pulses, and check for temporal artery tenderness, thickening, or pulselessness.
• Emergency Corticosteroid Therapy: Initiate treatment immediately if clinical suspicion is high; do not delay steroid administration to wait for a temporal artery biopsy.
• For patients WITH vision loss, diplopia, amaurosis fugax, or stroke-like symptoms (active cranial ischemia): Administer Methylprednisolone 500 to 1,000 mg intravenously (IV) piggyback daily for 3 consecutive days.
• For patients WITHOUT active vision loss or cranial ischemia: Administer Prednisone 40 to 60 mg orally (PO) (or 1 mg/kg/dose PO, maximum 80 mg daily) every 24 hours.
• Adjuvant Antithrombotic Therapy:
• In patients with suspected or documented large-vessel or flow-limiting involvement (e.g., carotid or vertebral stenosis), initiate Aspirin 81 mg PO daily in addition to high-dose systemic steroids.
• Monitored Resuscitation: Place the patient on a cardiorespiratory monitor to screen for reactive ischemic ECG changes or systemic complications if GCA presents with large-vessel aortic involvement.

3. THE DIAGNOSTIC GRID (Differential Diagnosis & Workup)

Top "Can't-Miss" Mimics

1. Central Retinal Artery Occlusion (CRAO) / Central Retinal Vein Occlusion (CRVO): Presents with sudden, painless monocular vision loss. Distinguish via fundoscopy (cherry-red spot in CRAO vs. blood-and-thunder disk in CRVO) and normal inflammatory markers.
2. Acute Angle-Closure Glaucoma: Presents with painful visual loss, corneal clouding, and a fixed, mid-dilated pupil. Differentiated by markedly elevated IOP on tonometry.
3. Acute Ischemic Stroke (specifically posterior circulation): Can present with diplopia, vertigo, or ataxia mimicking vertebral GCA. CTA/MRA of the head and neck can differentiate vascular dissection or atherothrombolism from vasculitic narrowing.
4. Takayasu Arteritis: A large-vessel vasculitis that can cause great vessel stenosis and claudication, but classically presents in young Asian women (<40 years old) rather than patients >50 years old.

Prioritized Diagnostic Workup Strategy

• Basic Labs: Complete blood count (CBC) to screen for anemia and thrombocytosis (reactive platelets), comprehensive metabolic panel (CMP), and urinalysis.
• Inflammatory Biomarkers: Order both Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP).
• Biomarker Cutoffs: ESR is typically elevated between 70 to 110 mm/hr in biopsy-proven cases (usually >50 mm/hr). CRP must be ≥10 mg/L (which serves as an ESR equivalent in newer diagnostic criteria).
• Utility: Normal levels of both markers significantly decrease the likelihood of GCA, though a negative result does not completely exclude it if clinical suspicion remains extremely high.
• Temporal Artery Biopsy Scheduling: Coordinate an urgent biopsy (the historical gold standard). Ensure it is performed within 1 week of starting steroids, as early steroid treatment does not decrease biopsy diagnostic yield.

4. THE VISUAL BOARD (ECG / POCUS / Imaging)

Standard ECG Visual Checklist

• Arrhythmia/Ischemia Screening: Monitor for silent myocardial ischemia, left ventricular hypertrophy, or reactive rhythm changes, especially in patients with associated large-vessel involvement or systemic cardiovascular risk.

Point-of-Care Ultrasound (POCUS) Findings

• The Temporal Artery "Halo Sign": Meticulously scan the superficial temporal arteries bilaterally using a high-frequency linear probe.
• Look for a periluminal hypoechoic halo surrounding the arterial lumen, which represents acute vessel wall edema.
• Significance: The presence of a validated "halo sign" on temporal artery ultrasound is now considered equivalent to a positive temporal artery biopsy under modern diagnostic criteria.

Neuroimaging Visual Checklist

• Dilated Retinal Examination: Meticulously examine the optic disk. Look for "pale papilloedema"—the classic finding where the ischemic optic disk appears pale, waxy, and elevated, often accompanied by adjacent splinter hemorrhages indicating anterior ischemic optic neuropathy.
• CT Angiography (CTA) or MRI of the Head and Neck:
• Role: Primarily used as adjunctive imaging to assess the extent of extra-cranial large-vessel involvement (e.g., axillary, carotid, or vertebral arteries).
• Visual Findings: Look for concentric arterial wall thickening, stenosis, or aneurysmal dilation. Bilateral axillary artery involvement on CTA/US or fluorodeoxyglucose-PET activity in the descending thoracic/abdominal aorta strongly supports the diagnosis of large-vessel GCA.

5. THE SCORING MATRIX (Risk Stratification & Guidelines)

1990 American College of Rheumatology (ACR) Classification Criteria

A classification of GCA is established if at least 3 of the following 5 criteria are met (Sensitivity 93.5%, Specificity 91.2%):

1. Age at disease onset ≥50 years.
2. New headache (new onset or new type of localized pain in the head).
3. Temporal artery abnormality (temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries).
4. ESR ≥50 mm/hr.
5. Positive artery biopsy showing vasculitis characterized by a dominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells.

2022 Revised ACR/EULAR Classification Criteria

A point-based scoring system where a score of ≥10 points is diagnostic for GCA, provided that medium- or large-vessel vasculitis has been established.

• Absolute Prerequisite: Age >50 years at diagnosis is now a mandatory requirement.
• Clinical Criteria:
• Morning stiffness in the shoulders/neck (PMR symptoms).
• Sudden vision loss.
• Jaw or tongue claudication.
• Scalp tenderness (now evaluated separately from temporal artery abnormalities).
• Temporal artery pulselessness, tenderness, or thickening.
• Laboratory, Imaging, and Biopsy Criteria:
• CRP ≥10 mg/L (or ESR ≥50 mm/hr).
• A "halo sign" on temporal artery ultrasound (equivalent to a positive biopsy).
• Bilateral axillary involvement on CTA, ultrasound, or PET scan.
• Fluorodeoxyglucose-PET activity within the descending thoracic and abdominal aorta.

6. THE DANGER ZONE (Pitfalls & Critical Actions)

Deadly Cognitive Traps & Trainee Pitfalls

• The "Biopsy Delay" Trap: Withholding or delaying high-dose steroid therapy because a temporal artery biopsy cannot be performed immediately in the ED. Critical Action: Administer steroids immediately; early treatment protects the eyes and does not affect biopsy results within the first week.
• Underestimating "Occult" GCA: Failing to consider GCA in an elderly patient presenting with isolated vision changes without a headache. Key Fact: Up to 38% of GCA patients can present with "occult" GCA (vision changes alone without classic cranial symptoms).
• Misattributing Jaw Claudication: Confounding jaw claudication with a standard temporomandibular joint (TMJ) disorder. Correction: GCA jaw claudication occurs strictly with chewing, completely resolves with rest, is highly reproducible, and does not occur with simple mouth opening.
• Discharging Active Cranial Ischemia: Sending a patient home who has ongoing or fluctuating vision loss, diplopia, or transient visual obscurations.

Mandated Board-Exam Critical Actions

• Document a formal bilateral visual acuity and a thorough pupillary exam (looking for a relative afferent pupillary defect [RAPD]) on every patient >50 years old presenting with a new headache or visual complaints.
• Ask about and document symptoms of Polymyalgia Rheumatica (PMR)—such as morning stiffness and symmetric proximal aching in the shoulder and hip girdles—which is present in up to 50% of GCA cases.
• Meticulously palpate the temples for tenderness, prominence, thickening, or decreased pulsation.

7. MCQ MASTERCLASS (Written Exam Tips)

High-Yield Exam "Buzzwords" and Associations

• "Most Common Vasculitis": GCA is the most common systemic vasculitis in adults in North America and Europe.
• "Scandinavian Descent": Highest incidence occurs in patients of Scandinavian or Northern European ancestry, and it is rare in Black patients.
• "Highly Specific Symptom": While headache is the most common symptom (72.2% sensitive), jaw claudication is the most specific symptom (92.3% specific), with a highly positive likelihood ratio (LR) of 4.9.
• "Morning Stiffness / PMR": Strong association with Polymyalgia Rheumatica; PMR is present in up to 50% of GCA patients.
• "The Halo Sign": The pathognomonic ultrasound finding of periluminal vessel wall edema, equivalent to a positive biopsy.

Differentiating Distractors

• Distractor: Dysphagia as a presenting symptom of GCA.
• Correction: Dysphagia is not a presenting feature of GCA; jaw or tongue claudication is the classic muscular/ischemic symptom.
• Distractor: Using Prednisone 60 mg PO for a patient presenting with active visual loss or amaurosis fugax.
• Correction: Oral prednisone is reserved for GCA patients without visual symptoms. Active vision loss is an ocular emergency requiring IV Methylprednisolone 500 to 1,000 mg.
• Distractor: Differentiating GCA from Takayasu Arteritis based on vessel size.
• Correction: Both are large-vessel vasculitides; the differentiator is age. GCA has an absolute requirement of age >50 years, while Takayasu typically presents in young females under 40 years old.

8. THE BOARDROOM SCRIPT (OSCE & Oral Board Tips)

Communication Pearls & Initial Script

• "Because this patient is over the age of 50 and presents with a new, atypical headache accompanied by visual disturbances, I recognize this as a high-stakes clinical scenario. I will place the patient in a monitored resuscitation bay, actively assess their airway, breathing, and circulation, and perform an immediate point-of-care capillary glucose to rule out hypoglycemia as a stroke mimic".
• "I will state clearly to my team: 'This patient has signs of acute cranial ischemia; we must treat this as an ocular emergency'. I will check a baseline visual acuity immediately, as this is the vital sign of the eye".

Mandatory Physical Exam Phrasing

• "I will perform a detailed neurological examination and a comprehensive ocular assessment, looking specifically for an afferent pupillary defect (RAPD), visual field cuts, or diplopia".
• "I will meticulously palpate the superficial temporal arteries bilaterally, checking for tenderness, prominence, thickening, or pulselessness".
• "I will perform a focused musculoskeletal examination, specifically assessing for symmetric shoulder and pelvic girdle tenderness, weakness, or limited range of motion to screen for associated Polymyalgia Rheumatica".
• "I will perform a fundoscopic examination, looking for pale, elevated, waxy disc swelling with splinter hemorrhages, which would indicate anterior ischemic optic neuropathy".

Smooth Articulation of Management Steps

• "Because this patient has active visual symptoms and a high clinical probability of GCA, I will initiate immediate medical therapy in the ED and will not delay treatment to wait for a biopsy. I will administer Methylprednisolone 1,000 mg intravenously as an infusion over 24 hours".
• "If the patient had no active visual deficits, I would instead initiate oral therapy with Prednisone 1 mg/kg, up to a maximum dose of 80 mg daily".
• "I will order basic laboratories, including a CBC, CMP, and urgent inflammatory markers, specifically an ESR and CRP".
• "I will perform a bedside point-of-care temporal artery ultrasound using a high-frequency linear probe. If I visualize a hypoechoic periluminal halo—the halo sign—this confirms GCA and is equivalent to a positive biopsy".
• "I will obtain an immediate ophthalmology and rheumatology consultation".
• "For my disposition, because this patient has ongoing vision loss, I will admit them to the hospital for continued high-dose intravenous steroids and close neuro-ophthalmic monitoring".
• "If the patient was completely stable with no visual or focal neurological deficits, I would consult rheumatology and arrange for a temporal artery biopsy within 1 week. I would safely discharge them home on oral prednisone with close outpatient follow-up and strongly worded return precautions regarding the risk of sudden visual loss, instructing them to return immediately for any visual changes, worsening headache, or jaw claudication".